Izokibep: "Part B HiSCR response at week 16 (primary endpoint NRI*)"; Hidradenitis Suppurativa (ACELYRIN) - Sep 15, 2023 - HS Top-Line Data Readout: "Izokibep response was dose ordered and safety results were consistent with prior experience, with no evidence of safety or tolerability limitation"
P2b data • Hidradenitis Suppurativa
|